연구동향 분석

Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer

윤승훈 최유덕 오인재 김규식 최하영 장진선 신홍준 박철규 김영철 2015년

논문상세정보
인용/피인용
' Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • erbb-1
  • genes
  • mutation
  • peptide nucleic acids
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,378 1

0.0%

' Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer' 의 참고문헌

  • Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    이재철 Cancer Research and Treatment 45 (2) : 79 ~ 85 [2013]
  • Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    이재철 Cancer Research and Treatment 45 2 79-85 [2013]
  • Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer
    Ludovini V J Thorac Oncol 6 : 707 ~ 715 [2011]
  • Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer
    Ludovini V J Thorac Oncol 6 707-715 [2011]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer EA Eur J Cancer 45 : 228 ~ 247 [2009]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer EA Eur J Cancer 45 228-247 [2009]
  • HER2 amplification : a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
    Takezawa K Cancer Discov 2 : 922 ~ 933 [2012]
  • HER2 amplification : a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation
    Takezawa K Cancer Discov 2 922-933 [2012]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 : 121 ~ 128 [2010]
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial
    Mitsudomi T Lancet Oncol 11 121-128 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 : 2380 ~ 2388 [2010]
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo M N Engl J Med 362 2380-2388 [2010]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 : 947 ~ 957 [2009]
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok TS N Engl J Med 361 947-957 [2009]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 : 239 ~ 246 [2012]
  • Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial
    Rosell R Lancet Oncol 13 239-246 [2012]
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study
    Zhou C Lancet Oncol 12 : 735 ~ 742 [2011]
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study
    Zhou C Lancet Oncol 12 735-742 [2011]
  • Erlotinib in lung cancer : molecular and clinical predictors of outcome
    Tsao MS N Engl J Med 353 : 133 ~ 144 [2005]
  • Erlotinib in lung cancer : molecular and clinical predictors of outcome
    Tsao MS N Engl J Med 353 133-144 [2005]
  • Epidermal growth factor receptor mutation testing in lung cancer : searching for the ideal method
    Pao W Clin Cancer Res 13 : 4954 ~ 4955 [2007]
  • Epidermal growth factor receptor mutation testing in lung cancer : searching for the ideal method
    Pao W Clin Cancer Res 13 4954-4955 [2007]
  • EGFR 돌연변이 검출에 있어 PNA-Mediated Real-Time PCR Clamping과 직접 염기서열 분석법의 비교 분석
    김희정 Tuberculosis and Respiratory Diseases 70 1 21-27 [2011]
  • EGFR assays in lung cancer
    Dacic S Adv Anat Pathol 15 : 241 ~ 247 [2008]
  • EGFR assays in lung cancer
    Dacic S Adv Anat Pathol 15 241-247 [2008]
  • Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity
    Han HS J Thorac Oncol 7 : 355 ~ 364 [2012]
  • Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity
    Han HS J Thorac Oncol 7 355-364 [2012]
  • Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    Kim HJ Lung Cancer 75 : 321 ~ 325 [2012]
  • Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
    Kim HJ Lung Cancer 75 321-325 [2012]
  • Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment
    이현주 Journal of Pathology and Translational Medicine 47 (1) : 52 ~ 60 [2013]
  • Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment
    이현주 Journal of Pathology and Translational Medicine 47 1 52-60 [2013]
  • Comparative analysis of peptide nucleic acid(PNA)-mediated real-time PCR clamping and DNA direct sequencing for EGFR mutation detection
    Kim HJ Tuberc Respir Dis 70 : 21 ~ 27 [2011]
  • Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS)
    Fukuoka M J Clin Oncol 29 : 2866 ~ 2874 [2011]
  • Biomarker analyses and final overall survival results from a phase III, randomized, openlabel, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS)
    Fukuoka M J Clin Oncol 29 2866-2874 [2011]
  • Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffinembedded tissue specimens of non-small cell lung cancer
    O'Donnell P BMC Cancer 13 : 210 ~ [2013]
  • Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffinembedded tissue specimens of non-small cell lung cancer
    O'Donnell P BMC Cancer 13 210- [2013]
  • Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers
    Yu HA Clin Cancer Res 19 : 2240 ~ 2247 [2013]
  • Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers
    Yu HA Clin Cancer Res 19 2240-2247 [2013]
  • Activating mutationsin the epidermal growth factor receptor underlying responsivenessof non-small-cell lung cancer to gefitinib
    Lynch TJ. N Engl J Med 350 : 2129 ~ 2139 [2004]
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib
    Lynch TJ N Engl J Med 350 2129-2139 [2004]